Bispecific antibodies (BsAbs) are uniquely constructed molecules composed of Fab and Fc fragments that merge cytotoxic immune cells with tumor cells to effect tumor cell lysis. They are off-the-shelf T-cell-based cancer immunotherapies that have distinct advantages over immune checkpoint inhibitors by being MHC molecule independent and do not rely on the complex manufacturing process involved in chimeric antigen T-cell therapies. First approved for hematologic malignancies, acute lymphoblastic leukemia, aggressive and indolent non-Hodgkin lymphoma (NHL) (diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL)), and multiple myeloma, bispecific antibodies such as amivantamab have indications for solid tumors. A new form of bispecific antibodies combining checkpoints such as CTLA-4, PD-1, and PD-1 are in development, and an investigational BsAb when combined with lenvatinib is showing efficacy in metastatic hepatocellular carcinoma. Immune-related adverse events such as hematologic malignancies, cytokine release syndrome, and immune effector cell–associated neurotoxicity syndrome (ICANS) accompany the administration of bispecific antibodies and must be appropriately managed.